Brookline raised the firm’s price target on Immunic (IMUX) to $22 from $19 and keeps a Buy rating on the shares after the company announced data from its Phase 2 CALLIPER trial of nuclear receptor related 1 activator, vidofludimus calcium, in patients with progressive multiple sclerosis. The trial results, which met the firm’s expectations, “meaningfully reduce development risk,” the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
- Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
- Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Dual Mechanism and Positive Trial Results Justifying Buy Rating
- Immunic Announces $5.1 Million Securities Purchase Agreement
- Immunic sells 5.67M shares at 90c in registered direct offering